Literature DB >> 9434825

Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutations.

C Panizo1, A Patiño, M J Calasanz, J Rifón, L Sierrasesumaga, E Rocha.   

Abstract

BACKGROUND: Secondary leukemia and myelodysplastic syndromes have been reported in patients following treatment for a wide range of neoplastic disorders. However second malignancies after chemotherapy and/or irradiation for osteosarcoma are unusual. PROCEDURE: We report the case of a 15-year-old girl who developed a myelodysplastic syndrome with evolution to acute nonlymphocytic leukemia after treatment for osteosarcoma. Therapy-related acute leukemia karyotype findings such as abnormalities of chromosomes 5, 7, and 17 were found in the cytogenetic analysis. Moreover, using denaturing gradient gel electrophoresis and DNA sequencing, we detected the presence of a double germline mutation in exon 7 of the TP53 gene.
CONCLUSION: This observation supports the possibility of a causal relationship between germline TP53 mutations and the development of secondary leukemia and myelodysplasia.

Entities:  

Mesh:

Year:  1998        PMID: 9434825     DOI: 10.1002/(sici)1096-911x(199803)30:3<165::aid-mpo7>3.0.co;2-f

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  5 in total

1.  Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

Authors:  J M Allan; C P Wild; S Rollinson; E V Willett; A V Moorman; G J Dovey; P L Roddam; E Roman; R A Cartwright; G J Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  Metachronous bilateral soft tissue sarcoma of the extremities.

Authors:  A Daigeler; M Lehnhardt; A Sebastian; O Belyaev; L Steinstraesser; H U Steinau; C Kuhnen
Journal:  Langenbecks Arch Surg       Date:  2007-01-23       Impact factor: 3.445

3.  Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.

Authors:  Daniel C Link; Laura G Schuettpelz; Dong Shen; Jinling Wang; Matthew J Walter; Shashikant Kulkarni; Jacqueline E Payton; Jennifer Ivanovich; Paul J Goodfellow; Michelle Le Beau; Daniel C Koboldt; David J Dooling; Robert S Fulton; R Hugh F Bender; Lucinda L Fulton; Kimberly D Delehaunty; Catrina C Fronick; Elizabeth L Appelbaum; Heather Schmidt; Rachel Abbott; Michelle O'Laughlin; Ken Chen; Michael D McLellan; Nobish Varghese; Rakesh Nagarajan; Sharon Heath; Timothy A Graubert; Li Ding; Timothy J Ley; Gerard P Zambetti; Richard K Wilson; Elaine R Mardis
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

4.  Association of CYP3A4 genotype with treatment-related leukemia.

Authors:  C A Felix; A H Walker; B J Lange; T M Williams; N J Winick; N K Cheung; B D Lovett; P C Nowell; I A Blair; T R Rebbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

5.  Secondary acute myeloid leukemia after successful treatment for osteosarcoma.

Authors:  Rakesh Mittal; N V Ramaswamy; R Pandita; S Al Bahar; N Khalifa; S Omar
Journal:  Indian J Med Paediatr Oncol       Date:  2010-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.